Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Hamlin

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Alimentary Pharmacology & Therapeutics|March 23, 2012
Commentary: outcomes after escalation of infliximab in moderately active ulcerative colitisS Halpin, P J Hamlin
Alimentary Pharmacology & Therapeutics|December 17, 2011
Anti-TNF associated psoriasisP J Hamlin, M Goodfield
Alimentary Pharmacology & Therapeutics|July 19, 2012
Commentary: infliximab or adalimumab in Crohn's disease?M B Sprakes, P J Hamlin
British Journal of Hospital Medicine (London, England : 2005)|January 19, 2010
Anti-tumour necrosis factor-alpha therapies in Crohn's diseaseM B Sprakes, P J Hamlin
Frontline Gastroenterology|August 26, 2017
Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011?S M Everett, P J Hamlin
Alimentary Pharmacology & Therapeutics|October 1, 2013
Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab?M B Sprakes, P J Hamlin
Alimentary Pharmacology & Therapeutics|December 17, 2011
Is propionyl-L-carnitine therapy effective in ulcerative colitis?L V B Turner, P J Hamlin
Alimentary Pharmacology & Therapeutics|November 6, 2010
Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitisS Thanaraj, P J Hamlin, A C Ford
Alimentary Pharmacology & Therapeutics|November 6, 2010
Effect of oral zinc in hepatic encephalopathy remains unclearJ Coughlan, P J Hamlin, A C Ford
Frontline Gastroenterology|August 26, 2017
Establishing a biologics service for patients with inflammatory bowel diseaseP J Hamlin, L Warren, S M Everett
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Alimentary Pharmacology & Therapeutics|March 23, 2012
Commentary: outcomes after escalation of infliximab in moderately active ulcerative colitisS Halpin, P J Hamlin
Alimentary Pharmacology & Therapeutics|December 17, 2011
Anti-TNF associated psoriasisP J Hamlin, M Goodfield
Alimentary Pharmacology & Therapeutics|July 19, 2012
Commentary: infliximab or adalimumab in Crohn's disease?M B Sprakes, P J Hamlin
British Journal of Hospital Medicine (London, England : 2005)|January 19, 2010
Anti-tumour necrosis factor-alpha therapies in Crohn's diseaseM B Sprakes, P J Hamlin
Frontline Gastroenterology|August 26, 2017
Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011?S M Everett, P J Hamlin
Alimentary Pharmacology & Therapeutics|October 1, 2013
Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab?M B Sprakes, P J Hamlin
Alimentary Pharmacology & Therapeutics|December 17, 2011
Is propionyl-L-carnitine therapy effective in ulcerative colitis?L V B Turner, P J Hamlin
Alimentary Pharmacology & Therapeutics|November 6, 2010
Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitisS Thanaraj, P J Hamlin, A C Ford
Alimentary Pharmacology & Therapeutics|November 6, 2010
Effect of oral zinc in hepatic encephalopathy remains unclearJ Coughlan, P J Hamlin, A C Ford
Frontline Gastroenterology|August 26, 2017
Establishing a biologics service for patients with inflammatory bowel diseaseP J Hamlin, L Warren, S M Everett
Pageof 3